Reversible segmental cerebral vasoconstriction (Call-Fleming syndrome): are calcium channel inhibitors a potential treatment option?

The Call-Fleming syndrome is characterized by sudden onset of thunderclap-like headache and focal neurological deficits. The pathophysiological correlate is a reversible segmental cerebral vasoconstriction frequently associated with focal cerebral ischaemia. The syndrome has been described in a variety of clinical conditions, and recently an association between the syndrome and exposure to vasoactive drugs was observed. Effective treatment options are not known. A 63-year-old female developed sudden 'worst ever' headache. Initial neurological examination, laboratory blood tests, CSF examination and brain magnetic resonance imaging (MRI) were normal. Previous medical history was unremarkable and she did not take vasoactive drugs. Eleven days after the onset of headache she developed visual field impairment and a right-sided hemiparesis. Brain MRI revealed bilateral posterior and left parietal ischaemic strokes. Cerebral catheter angiography showed segmental arterial vasoconstriction. A vasodilative therapy with calcium channel inhibitors was started and serial transcranial Doppler ultrasonography demonstrated resolution of cerebral arterial vasoconstriction. The present case illustrates that calcium channel inhibitors may be an effective therapy for segmental cerebral arterial vasoconstriction. However, more clinical data are needed to prove this observation.

Pulmonary nodules: experimental and clinical studies at low-dose CT.

PURPOSE: To compare the number of pulmonary nodules detected at helical low- and standard-dose computed tomography (CT) and to investigate the diagnostic value of low-dose CT with a radiation exposure equivalent to that used at chest radiography. MATERIALS AND METHODS: Two radiologists recorded pulmonary nodules at standard-dose (250 or 100 mA, pitch of 1; 200 mA, pitch of 2) or low-dose CT (50 or 25 mA, pitch of 1 or 2) in five postmortem specimens and 75 patients. Nodules were assessed by size (5 mm or smaller, 6-10 mm, or larger than 10 mm) and by diagnostic confidence ("definite nodule," "definite lesion, not classic nodule," or "questionable lesion, possibly representing a vessel") with the Wilcoxon signed rank test. Artifacts depicted at low-dose CT were recorded. RESULTS: There were no statistically significant differences in the number of nodules detected at standard- or low-dose CT except in nodules 5 mm or smaller that were assessed as definite nodules at standard- or low-dose CT (25 mA, pitch of 2) (472 vs 397, P < .05). Artifacts that possibly interfered with nodule detection were observed exclusively at CT with 25 mA and a pitch of 2. CONCLUSION: Pulmonary nodules were detected reliably at CT with 50 mA and pitch of 2 or with 25 mA and a pitch of 1. However, further reduction of the dose to that used at chest radiography was associated with a significant decrease in the number of nodules 5 mm or smaller that were detected, possibly due to artifacts.